Jian Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jian Lu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Ang Wang
Department of Orthopaedic Surgery Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
1 shared publicationChang‐Ru Zhang
Shanghai Key Laboratory of Orthopaedic Implants Department of Orthopaedic Surgery Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
1 shared publication- Cheng Qu
Department of Orthopedics, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
1 shared publication - Cunyi Fan
Department of Orthopedics, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
1 shared publication Fei Wang
Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases Shanghai Institute of Traumatology and Orthopaedics Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
1 shared publication- Helen Dawes
Faculty of Health and Life Science Oxford Brookes University Oxford UK
1 shared publication
Latest Publications
- 3 November 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
Pharmacological Inhibition of STING with H-151 Promotes Rotator Cuff Healing in Aged Rats
Background: Although the cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) pathway is a key driver of inflammaging in age-related musculoskeletal disorders, its role in age-related rotator cuff tears (RCTs) remains unknown. This study investigated whether inhibition of the cGAS-STING pathway with H-151 could improve tendon-to-bone healing in aged rats after rotator cuff repair (RCR). Methods: Forty-eight Sprague-Dawley rats were assigned to 4 groups: young control (sham surgery), aged control (sham surgery), aged RCT (RCR with fibrin), and aged RCT+H-151 (RCR with H-151-loaded fibrin). Rats in the RCT groups underwent bilateral RCR, after which the tendon-bone enthesis was treated with the respective fibrin gel. The status of the cGAS-STING pathway, expression of inflammaging and differentiation markers, and histological and biomechanical properties of the supraspinatus-humerus complex were evaluated. Results: The cGAS-STING pathway was markedly activated at the tendon-bone enthesis in the aged rats. Treatment with H-151 effectively suppressed its downstream effectors ( Ifnb and Cxcl10 ), reduced inflammaging markers ( Cdkn2a, Cdkn1a, Il1b, and Il6 ), and enhanced the expression of chondrogenic ( Acan and Col2a1 ) and tenogenic ( Tnmd and Scx ) differentiation markers. Histological assessment revealed improved collagen organization and enhanced cartilage regeneration at the enthesis in the aged RCT+H-151 group, which also achieved a higher histological score. Biomechanically, the aged RCT+H-151 group exhibited significantly increased failure load, stiffness, and tensile stress compared with the aged RCT group. Conclusions: The cGAS-STING pathway was activated at the tendon-bone enthesis in aged rats. The inhibition of STING with H-151 in similar rats attenuated inflammaging, promoted collagen maturation and fibrocartilage regeneration, and substantially improved the biomechanical properties of the repaired enthesis. Clinical Relevance: Inhibition of the cGAS-STING pathway using STING antagonists may be a promising therapeutic strategy for enhancing rotator cuff healing in older patients.
- 3 November 2026
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
Pharmacological Inhibition of STING with H-151 Promotes Rotator Cuff Healing in Aged Rats
Background: Although the cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) pathway is a key driver of inflammaging in age-related musculoskeletal disorders, its role in age-related rotator cuff tears (RCTs) remains unknown. This study investigated whether inhibition of the cGAS-STING pathway with H-151 could improve tendon-to-bone healing in aged rats after rotator cuff repair (RCR). Methods: Forty-eight Sprague-Dawley rats were assigned to 4 groups: young control (sham surgery), aged control (sham surgery), aged RCT (RCR with fibrin), and aged RCT+H-151 (RCR with H-151-loaded fibrin). Rats in the RCT groups underwent bilateral RCR, after which the tendon-bone enthesis was treated with the respective fibrin gel. The status of the cGAS-STING pathway, expression of inflammaging and differentiation markers, and histological and biomechanical properties of the supraspinatus-humerus complex were evaluated. Results: The cGAS-STING pathway was markedly activated at the tendon-bone enthesis in the aged rats. Treatment with H-151 effectively suppressed its downstream effectors ( Ifnb and Cxcl10 ), reduced inflammaging markers ( Cdkn2a, Cdkn1a, Il1b, and Il6 ), and enhanced the expression of chondrogenic ( Acan and Col2a1 ) and tenogenic ( Tnmd and Scx ) differentiation markers. Histological assessment revealed improved collagen organization and enhanced cartilage regeneration at the enthesis in the aged RCT+H-151 group, which also achieved a higher histological score. Biomechanically, the aged RCT+H-151 group exhibited significantly increased failure load, stiffness, and tensile stress compared with the aged RCT group. Conclusions: The cGAS-STING pathway was activated at the tendon-bone enthesis in aged rats. The inhibition of STING with H-151 in similar rats attenuated inflammaging, promoted collagen maturation and fibrocartilage regeneration, and substantially improved the biomechanical properties of the repaired enthesis. Clinical Relevance: Inhibition of the cGAS-STING pathway using STING antagonists may be a promising therapeutic strategy for enhancing rotator cuff healing in older patients.
- Open Access
- 14 October 2026
- Published by Wiley in Advanced Science
- p. e78104
Yoda1‐Functionalized Nanozymes Coordinate Piezo1 Activation and Mitochondrial Protection to Reprogram the Diabetic Osteoimmune Micromilieu and Promote Vascularized Bone Repair
Despite advances in bone tissue engineering, repairing diabetic bone defects remains a formidable challenge. Here, we present an innovative strategy for diabetic bone regeneration, the BCPG‐MF@Y scaffold, which features diamond lattices of 3D‐printed biphasic calcium phosphate (BCP) integrating porous gelatine methacryloyl (pGelMA) hydrogels embedded with Yoda1‐functionalized manganese dioxide‐ferritin (MF@Y) biomimetic nanozymes. Our comprehensive analyses revealed that the MF@Y nanozyme orchestrates mitochondrial homeostasis in bone mesenchymal stem cells (BMSCs), effectively scavenges mtROS, maintains mitochondrial membrane potential, modulates mitochondrial permeability transition pore dynamics, and prevents mitochondrial DNA leakage into the cytosol. This leads to inhibition of cGAS‒STING pathway activation, rejuvenation of senescent cells, reduced inflammation, and control of BMSC differentiation. Yoda1‐mediated activation of Piezo1 mimics mechanical stimulation, promoting osteogenic differentiation while inhibiting adipogenic and osteoclastic differentiation. The BCPG‐MF@Y scaffold synergistically reprograms the osteoimmune micromilieu by protecting mitochondria and activating Piezo1, showing significant promise for vascularized bone repair in diabetic conditions and potential applications in chronic inflammatory disorders.
- 14 October 2026
- Published by Wiley in Advanced Science
- p. e78104
Open AccessYoda1‐Functionalized Nanozymes Coordinate Piezo1 Activation and Mitochondrial Protection to Reprogram the Diabetic Osteoimmune Micromilieu and Promote Vascularized Bone Repair
Despite advances in bone tissue engineering, repairing diabetic bone defects remains a formidable challenge. Here, we present an innovative strategy for diabetic bone regeneration, the BCPG‐MF@Y scaffold, which features diamond lattices of 3D‐printed biphasic calcium phosphate (BCP) integrating porous gelatine methacryloyl (pGelMA) hydrogels embedded with Yoda1‐functionalized manganese dioxide‐ferritin (MF@Y) biomimetic nanozymes. Our comprehensive analyses revealed that the MF@Y nanozyme orchestrates mitochondrial homeostasis in bone mesenchymal stem cells (BMSCs), effectively scavenges mtROS, maintains mitochondrial membrane potential, modulates mitochondrial permeability transition pore dynamics, and prevents mitochondrial DNA leakage into the cytosol. This leads to inhibition of cGAS‒STING pathway activation, rejuvenation of senescent cells, reduced inflammation, and control of BMSC differentiation. Yoda1‐mediated activation of Piezo1 mimics mechanical stimulation, promoting osteogenic differentiation while inhibiting adipogenic and osteoclastic differentiation. The BCPG‐MF@Y scaffold synergistically reprograms the osteoimmune micromilieu by protecting mitochondria and activating Piezo1, showing significant promise for vascularized bone repair in diabetic conditions and potential applications in chronic inflammatory disorders.
- Open Access
- 4 August 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-11
Exosomes in the Repair of Bone Defects: Next-Generation Therapeutic Tools for the Treatment of Nonunion
Nonunion with bone defects, a common complication after long bone fracture, is a major challenge for orthopaedic surgeons worldwide because of the high incidence rate and difficulties in achieving successful treatment. Bone defects are the main complications of nonunion. The conventional biological treatments for nonunion with bone defects involve the use of autologous bone grafts or bone graft substitutes and cell-based therapy. Traditional nonunion treatments have always been associated with safety issues and various other complications. Bone grafts have limited autologous cancellous bone and there is a risk of infection. Additionally, problems with bone graft substitutes, including rejection and stimulation of bone formation, have been noted, and the health of the stem cell niche is a major consideration in cell-based therapy. In recent years, researchers have found that exosomes can be used to deliver functional RNA and mediate cell-to-cell communication, suggesting that exosomes may repair bone defects by regulating cells and cytokines involved in bone metabolism. In this review, we highlight the possible relationships between risk factors for nonunion and exosomes. Additionally, we discuss the roles of exosomes in bone metabolism and bone regeneration.
- 4 August 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-11
Open AccessExosomes in the Repair of Bone Defects: Next-Generation Therapeutic Tools for the Treatment of Nonunion
Nonunion with bone defects, a common complication after long bone fracture, is a major challenge for orthopaedic surgeons worldwide because of the high incidence rate and difficulties in achieving successful treatment. Bone defects are the main complications of nonunion. The conventional biological treatments for nonunion with bone defects involve the use of autologous bone grafts or bone graft substitutes and cell-based therapy. Traditional nonunion treatments have always been associated with safety issues and various other complications. Bone grafts have limited autologous cancellous bone and there is a risk of infection. Additionally, problems with bone graft substitutes, including rejection and stimulation of bone formation, have been noted, and the health of the stem cell niche is a major consideration in cell-based therapy. In recent years, researchers have found that exosomes can be used to deliver functional RNA and mediate cell-to-cell communication, suggesting that exosomes may repair bone defects by regulating cells and cytokines involved in bone metabolism. In this review, we highlight the possible relationships between risk factors for nonunion and exosomes. Additionally, we discuss the roles of exosomes in bone metabolism and bone regeneration.